具有可调节保留的矩阵金属蛋白酶响应的水凝,用于按需治疗炎症性肠病
Xueyong Xie1, Yaohui Wang1, Bo Deng1
1The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, PR China; Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an 710049, PR China.
Acta biomaterialia
|August 8, 2024
概括
这项研究引入了一种用于炎症性肠病 (IBD) 治疗的新型水凝阴道系统. 该系统提供可控的药物释放和保留时间,提高IBD患者的治疗疗效和安全性.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 药物输送系统 药物输送系统
背景情况:
- 无法控制的阴囊保留挑战了炎症性肠病 (IBD) 的治疗疗效和安全性.
- 矩阵金属蛋白酶-9 (MMP-9) 在IBD中高度表达,与疾病严重程度相关,具有治疗点.
研究的目的:
- 开发一种蛋白酶性水凝系统,用于在IBD中按需输送阴囊.
- 创建一个可调节的降解和药物释放率响应MMP-9表达的系统.
主要方法:
- 开发了一种使用多臂聚乙烯糖醇 (PEG) 和通过动态水键交叉连接的等的水凝系统.
- 调的水凝网络连接和降解率通过不同的PEG臂数 (2,4,8).
- 在急性结肠炎的小鼠模型中评估了体内治疗效果,包括MMP-9消耗和结肠组织修复.
主要成果:
- 实现了可调节的水凝保留时间从12小时到36小时,并控制了药物释放率 (0.00030.278 mg/h).
- 在大肠炎小鼠模型中表现出显著的治疗改善,GP-8/5-ASA显示出最佳性能.
- 展示了与PEG手臂数量和MMP-9水平相关的治疗效果的差异.
结论:
- 针对病态微环境线索的定制水凝架构对IBD治疗有效.
- 响应MMP-9的水凝系统是按需IBD治疗的有希望的策略.
- 这种方法为开发各种严重程度的疾病的刺激响应药物输送系统提供了洞察力.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109
01:23Role of Matrix Metalloproteases in Degradation of ECM
2.3K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149